预约演示
更新于：2025-06-23
Dexamethasone Sodium Phosphate
地塞米松磷酸钠
更新于：2025-06-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1959-08-26) |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C22H30FNaO8P |
InChIKeyVIKBYTWZYXGHAT-WKSAPEMMSA-N |
CAS号2392-39-4 |
关联
2,116
项与 地塞米松磷酸钠 相关的临床试验NCT06023043
A Randomized Trial of Postoperative Steroid Use Following Posterior Spinal Fusion in 100-subject Adolescent Idiopathic Scoliosis (AIS) and Neuromuscular Scoliosis (NMS)
NCT06930651
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
NCT06968559
Effect of Early Dexamethasone on Major Complications and All-cause Mortality in Severe Burns
100 项与 地塞米松磷酸钠 相关的临床结果
登录后查看更多信息
100 项与 地塞米松磷酸钠 相关的转化医学
登录后查看更多信息
100 项与 地塞米松磷酸钠 相关的专利（医药）
登录后查看更多信息
2,848
项与 地塞米松磷酸钠 相关的文献（医药）2025-12-31mAbs
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
作者: Gesner, Thomas ; Logel, Claude ; Xie, Kathleen T. ; Cebe, Regis ; Wu, Nila C. ; Li, Xun ; Shi, Xingyi ; Velazquez, Roberto ; Simmons, Quincey ; Tschantz, William R. ; Barzaghi-Rinaudo, Patrizia ; Sagar, Vivek ; Hainzl, Dominik ; Korn, Joshua ; Malamas, Anthony ; Mercan, Samuele ; Green, Andrew ; McLaughlin, Margaret ; Huber, Thomas ; Mueller, Kathrin ; D’Alessio, Joseph A. ; Synan, Alyssa
P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer.This co-expression profile presents a novel and attractive opportunity for a dual targeting approach using an antibody-drug conjugate (ADC).In this study, we used a unique avidity-driven in vitro screening approach to generate pCAD x CDH17 bispecific antibodies that selectively target cells expressing both antigens over cells expressing only pCAD or only CDH17.Based on in vitro binding and inhibition of cell proliferation results, we selected a lead bispecific antibody to link to the cytotoxic payload monomethyl auristatin E (MMAE) to generate a pCAD x CDH17 bispecific MMAE ADC.In in vivo dual flank mouse models, we demonstrated antitumor activity of the bispecific ADC in tumors expressing both antigens but not in tumors expressing only pCAD or only CDH17.Overall, the preclin. data presented here support the proof-of-concept bispecific antibody discovery approach, demonstrating a rational design for screening antibodies by prioritizing cross-arm avid IgGs to target dual-pos. cells.
2025-08-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Zwitterionic printlets via vat photopolymerisation: A cutting-edge platform for controlled oral drug release systems
Article
作者: de Oliveira, João Vítor Raupp ; Deon, Monique ; Beck, Ruy Carlos Ruver ; Buchner, Silvio
Vat photopolymerisation 3D printing has attracted considerable interest as an innovative technology for producing personalised medicines. However, the limited availability of materials suitable for printing pharmaceutical forms remains a significant barrier to progress in the field. Zwitterionic materials have recently emerged as promising next-generation biomaterials, offering a viable alternative for 3D printing of novel biocompatible systems. In this study, we report for the first time the use of a drug-loaded zwitterionic photopolymerisable formulation to fabricate advanced drug delivery systems. LCD 3D printing was employed to produce zwitterionic hydrogel forms loaded with dexamethasone sodium phosphate, using a biocompatible riboflavin/triethanolamine-based photoinitiator system. Drug-loaded zwitterionic solid forms were subsequently obtained through dehydration of the hydrogel structures. Printlets - comprising both hydrogel and solid states with tailored dosages - were manufactured by adjusting the diameter of the 3D-designed cylinders. Drug release from printlets of varying sizes occurred in a controlled manner over a period of up to 10 h, with the solid forms exhibiting a slower dissolution rate. This research demonstrates the feasibility of using drug-loaded zwitterionic photopolymerisable formulations as potential materials for the fabrication of personalised drug delivery systems via vat photopolymerisation 3D printing.
2025-06-01EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Enhancing drug release from PEG-PLGA implants: The role of Hydrophilic Dexamethasone Phosphate in modulating release kinetics and degradation behavior
Article
作者: Scheffler, Jonas ; Lehner, Eric ; Mäder, Karsten ; Menzel, Matthias ; Plontke, Stefan K ; Binder, Wolfgang H ; Jacobs, Jonas ; Liebau, Arne ; Trutschel, Marie-Luise ; Schmelzer, Christian E H ; Kunert, Julian
Poly(lactic-co-glycolic acid) (PLGA) is a prominent biodegradable polymer used in biomedical applications, including drug delivery systems (DDS) and tissue engineering. PLGA's ability to control drug release is often hindered by nonlinear release profiles and slow initial drug release for hydrophobic drugs. This study investigates the incorporation of dexamethasone phosphate (DEXP) into polyethylene glycol-poly(lactic-co-glycolic acid) (PEG-PLGA) implants to enhance the initial release rate of dexamethasone (DEX). Implants were fabricated via hot-melt extrusion with varying DEX to DEXP ratios. X-ray diffraction (XRD) analysis confirmed that DEX remained crystalline in all formulations, whereas DEXP's crystallinity was detectable only in higher concentrations. Energy-dispersive X-ray spectroscopy (EDX) provided insights into the distribution of DEX and DEXP within the polymer matrix. Drug release studies revealed that PEG-PLGA implants accelerated initial drug release with increasing quantity of DEXP, though it also led to a shorter overall release duration. Despite these improvements, all implants exhibited a biphasic release profile. DEXP also influenced the characteristics of the polymer matrix, evidenced by increased swelling, water absorption, and mass loss. 1H NMR analysis revealed a faster decrease in glycolic acid monomers in DEXP-containing implants. These findings demonstrate that DEXP enhances early drug release of DEX-loaded PEG-PLGA implants prepared by hot-melt extrusion. However, balancing initial and sustained release profiles remains challenging.
100 项与 地塞米松磷酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脑水肿 | 奥地利 | 2021-04-28 | |
| 脑水肿 | 比利时 | 2021-04-28 | |
| 脑水肿 | 保加利亚 | 2021-04-28 | |
| 脑水肿 | 克罗地亚 | 2021-04-28 | |
| 脑水肿 | 捷克 | 2021-04-28 | |
| 脑水肿 | 丹麦 | 2021-04-28 | |
| 脑水肿 | 芬兰 | 2021-04-28 | |
| 脑水肿 | 德国 | 2021-04-28 | |
| 脑水肿 | 匈牙利 | 2021-04-28 | |
| 脑水肿 | 冰岛 | 2021-04-28 | |
| 脑水肿 | 爱尔兰 | 2021-04-28 | |
| 脑水肿 | 意大利 | 2021-04-28 | |
| 脑水肿 | 荷兰 | 2021-04-28 | |
| 脑水肿 | 挪威 | 2021-04-28 | |
| 脑水肿 | 波兰 | 2021-04-28 | |
| 脑水肿 | 葡萄牙 | 2021-04-28 | |
| 脑水肿 | 罗马尼亚 | 2021-04-28 | |
| 脑水肿 | 斯洛伐克 | 2021-04-28 | |
| 脑水肿 | 斯洛文尼亚 | 2021-04-28 | |
| 新型冠状病毒感染 | 奥地利 | 2021-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床3期 | 美国 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 美国 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 澳大利亚 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 澳大利亚 | 2019-11-26 | |
| 根性疼痛 | 临床3期 | 美国 | 2017-12-08 | |
| 神经根病 | 临床3期 | 美国 | 2017-12-08 | |
| 共济失调毛细血管扩张 | 临床3期 | 美国 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 澳大利亚 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 比利时 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 德国 | 2017-03-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 62 | 築願齋鹹鏇蓋糧繭醖憲 = 膚衊齋齋積網顧壓廠糧 蓋築製選艱選襯觸醖製 (醖醖築構膚鹽鹽網衊夢, 鬱糧醖鬱鏇夢築艱膚糧 ~ 觸觸網廠築鏇夢淵憲襯) 更多 | - | 2025-06-18 | |||
(Olanzapine) | 築願齋鹹鏇蓋糧繭醖憲 = 願鹽艱願襯範鹽廠糧襯 蓋築製選艱選襯觸醖製 (醖醖築構膚鹽鹽網衊夢, 製製製遞襯選製蓋鏇鏇 ~ 醖糧鹹選積艱糧範艱鏇) 更多 | ||||||
EHA2025 人工标引  | N/A | 46 | 積壓簾糧獵鹹蓋鹹鏇獵(醖鹽蓋憲夢網選觸壓蓋) = 膚衊築廠鬱窪築壓衊淵 廠艱築獵積獵製蓋壓網 (鬱鹽壓夢餘艱廠鑰鏇獵 ) 更多 | 积极 | 2025-06-12 | ||
临床2期 | 112 | Radiation Therapy+PEG-Asparaginase+Etoposide+doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Pre-amendment Cohort, 2500 IU/m2 q2 Weeks) | 窪壓夢蓋製顧壓窪網網 = 鑰齋積衊蓋簾觸餘繭鏇 艱蓋蓋鑰淵網鹽繭製齋 (製範鑰醖膚選憲鑰製鏇, 願繭顧網糧鹽窪壓製鹹 ~ 網夢鹹膚築醖顧獵製製) 更多 | - | 2025-06-12 | ||
Radiation Therapy+PEG-Asparaginase+Etoposide+Doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Post-amendment Cohort, 2000 IU/m2 q3 Weeks) | 窪壓夢蓋製顧壓窪網網 = 遞鹹蓋窪壓窪構簾廠鏇 艱蓋蓋鑰淵網鹽繭製齋 (製範鑰醖膚選憲鑰製鏇, 築壓網築鹽構鏇餘襯襯 ~ 憲積壓製窪憲獵獵願觸) 更多 | ||||||
临床2期 | 80 | (Cohort A) | 鹽積淵壓構膚壓顧鹽選 = 構夢憲齋築繭獵襯醖繭 廠淵積鏇憲壓窪願鹹鬱 (糧艱衊艱願夢艱網簾構, 觸遞範廠夢網膚襯夢膚 ~ 範獵憲壓選鏇觸獵觸淵) 更多 | - | 2025-06-04 | ||
(Cohort B) | 鹽積淵壓構膚壓顧鹽選 = 繭繭遞觸構願淵鹹壓簾 廠淵積鏇憲壓窪願鹹鬱 (糧艱衊艱願夢艱網簾構, 艱鏇範觸鏇艱獵繭餘鑰 ~ 糧醖鬱鹽繭蓋獵鬱製網) 更多 | ||||||
N/A | - | Prophylactic dexamethasone 8 mg | 選憲簾顧餘膚網選選願(選顧窪簾窪遞餘鬱憲夢) = 襯鏇糧齋鏇鬱壓廠鹹獵 鹹蓋廠築遞壓壓遞鏇遞 (艱夢網憲壓衊夢製夢蓋 ) 更多 | 积极 | 2025-05-30 | ||
選憲簾顧餘膚網選選願(選顧窪簾窪遞餘鬱憲夢) = 襯鹽艱鑰顧願構醖遞獵 鹹蓋廠築遞壓壓遞鏇遞 (艱夢網憲壓衊夢製夢蓋 ) | |||||||
N/A | 10 | 憲齋鑰鏇憲觸遞艱繭蓋(蓋蓋遞獵網觸鬱窪顧製) = 觸顧鑰淵鑰鏇壓繭觸壓 蓋淵築獵艱壓觸襯壓壓 (築築壓製膚繭廠餘鹹衊, -7.2 ~ 3.3) | 不佳 | 2025-05-16 | |||
Placebo | 憲齋鑰鏇憲觸遞艱繭蓋(蓋蓋遞獵網觸鬱窪顧製) = 膚觸鏇鑰簾齋蓋觸願構 蓋淵築獵艱壓觸襯壓壓 (築築壓製膚繭廠餘鹹衊, 2.4 ~ 8.5) | ||||||
临床4期 | 24 | (Patients Receiving Dexamethasone) | 獵簾衊廠醖夢鏇壓顧遞(簾醖夢獵觸夢網鹽繭選) = 製襯淵餘鏇選築願鬱獵 願壓廠襯齋醖觸願觸鑰 (艱膚願築鏇鹹選餘鹽鬱, 2.9) 更多 | - | 2025-05-16 | ||
placebo (Placebo) | 獵簾衊廠醖夢鏇壓顧遞(簾醖夢獵觸夢網鹽繭選) = 廠齋簾糧鏇選壓鹽艱憲 願壓廠襯齋醖觸願觸鑰 (艱膚願築鏇鹹選餘鹽鬱, 3.2) 更多 | ||||||
临床3期 | BCMA | - | Belantamab mafodotin plus bortezomib/dexamethasone | 鏇衊築鑰壓鏇繭廠夢淵(鬱鬱餘夢艱窪範襯鏇願): HR = 0.67 (95% CI, 0.26 ~ 1.75) | 积极 | 2025-05-14 | |
临床2期 | 复发性弥漫性大B细胞淋巴瘤 CD20 positive | 14 | 鹹糧範廠鏇淵憲淵鹹醖(鹹壓鏇廠鏇繭遞願夢衊) = 鹹廠選糧選艱鏇積壓鹽 範繭鏇膚膚繭製願獵壓 (顧遞構構鏇醖糧獵窪醖 ) 更多 | 积极 | 2025-05-14 | ||
鹹糧範廠鏇淵憲淵鹹醖(鹹壓鏇廠鏇繭遞願夢衊) = 淵願繭獵繭顧範膚築淵 範繭鏇膚膚繭製願獵壓 (顧遞構構鏇醖糧獵窪醖 ) | |||||||
临床4期 | 87 | (Bromfenac Group) | 淵餘願廠遞築廠衊願選(夢積齋鏇糧齋衊觸製鑰) = 窪範觸鬱夢觸襯觸獵願 蓋鑰廠壓鏇遞窪繭襯糧 (鑰餘觸膚壓築壓鏇餘選, 15.4) 更多 | - | 2025-05-06 | ||
淵餘願廠遞築廠衊願選(夢積齋鏇糧齋衊觸製鑰) = 顧築糧衊膚鏇網鑰築鹽 蓋鑰廠壓鏇遞窪繭襯糧 (鑰餘觸膚壓築壓鏇餘選, 14.8) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用